BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Furuta M, Kikuchi H, Shoji T, Takashima Y, Kikuchi E, Kikuchi J, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail. Cancer Sci 2019;110:1599-608. [PMID: 30874360 DOI: 10.1111/cas.13997] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Muscarella LA, Mazza T, Fabrizio FP, Sparaneo A, D'Alessandro V, Tancredi A, Trombetta D, Centra F, Muscarella SP, Di Micco CM, Rossi A. Neuroendocrine-Related Circulating Transcripts in Small-Cell Lung Cancers: Detection Methods and Future Perspectives. Cancers (Basel) 2021;13:1339. [PMID: 33809582 DOI: 10.3390/cancers13061339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 2020;126:3192-201. [PMID: 32401342 DOI: 10.1002/cncr.32909] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
3 Batchu S, Hakim A, Henry OS, Madzo J, Atabek U, Spitz FR, Hong YK. Transcriptome-guided resolution of tumor microenvironment interactions in pheochromocytoma and paraganglioma subtypes. J Endocrinol Invest 2022. [PMID: 35088383 DOI: 10.1007/s40618-021-01729-8] [Reference Citation Analysis]
4 Huang W, Chen JJ, Xing R, Zeng YC. Combination therapy: Future directions of immunotherapy in small cell lung cancer. Transl Oncol 2021;14:100889. [PMID: 33065386 DOI: 10.1016/j.tranon.2020.100889] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
5 Xue T, Zhao X, Zhao K, Lu Y, Yao J, Ji X. Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. Curr Probl Cancer 2021;:100791. [PMID: 34538649 DOI: 10.1016/j.currproblcancer.2021.100791] [Reference Citation Analysis]
6 Meijer JJ, Leonetti A, Airò G, Tiseo M, Rolfo C, Giovannetti E, Vahabi M. Small cell lung cancer: novel treatments beyond immunotherapy. Semin Cancer Biol 2022:S1044-579X(22)00115-8. [PMID: 35568295 DOI: 10.1016/j.semcancer.2022.05.004] [Reference Citation Analysis]
7 Bian W, Tang M, Jiang H, Xu W, Hao W, Sui Y, Hou Y, Nie L, Zhang H, Wang C, Li N, Wang J, Qin J, Wu L, Ma X, Chen J, Wang W, Li X. Low-density-lipoprotein-receptor-related protein 1 mediates Notch pathway activation. Dev Cell 2021;56:2902-2919.e8. [PMID: 34626540 DOI: 10.1016/j.devcel.2021.09.015] [Reference Citation Analysis]
8 Chen W, Liu N, Shen S, Zhu W, Qiao J, Chang S, Dong J, Bai M, Ma L, Wang S, Jia W, Guo X, Li A, Xi J, Jiang C, Kang J. Fetal growth restriction impairs hippocampal neurogenesis and cognition via Tet1 in offspring. Cell Rep 2021;37:109912. [PMID: 34731622 DOI: 10.1016/j.celrep.2021.109912] [Reference Citation Analysis]
9 Nandi A, Chakrabarti R. The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance. Genes Dev 2020;34:1422-38. [PMID: 33872192 DOI: 10.1101/gad.342287.120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Ranallo N, Bocchini M, Menis J, Pilotto S, Severi S, Liverani C, Bongiovanni A. Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin. Expert Rev Anticancer Ther 2022. [PMID: 35477310 DOI: 10.1080/14737140.2022.2071703] [Reference Citation Analysis]
11 Rojo F, Corassa M, Mavroudis D, Öz AB, Biesma B, Brcic L, Pauwels P, Sailer V, Gosney J, Miljkovic D, Hader C, Wu M, Almarez T, Penault-Llorca F. International real-world study of DLL3 expression in patients with small cell lung cancer. Lung Cancer 2020;147:237-43. [PMID: 32745892 DOI: 10.1016/j.lungcan.2020.07.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Yuan C, Chang K, Xu C, Li Q, Du Z. High expression of DLL3 is associated with a poor prognosis and immune infiltration in invasive breast cancer patients. Transl Oncol 2021;14:101080. [PMID: 33915517 DOI: 10.1016/j.tranon.2021.101080] [Reference Citation Analysis]
13 von Arx C, Capozzi M, López-Jiménez E, Ottaiano A, Tatangelo F, Di Mauro A, Nasti G, Tornesello ML, Tafuto S. Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms. J Clin Med 2019;8:E1277. [PMID: 31443481 DOI: 10.3390/jcm8091277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
14 Chocarro L, Arasanz H, Fernández-rubio L, Blanco E, Echaide M, Bocanegra A, Teijeira L, Garnica M, Morilla I, Martínez-aguillo M, Piñeiro-hermida S, Ramos P, Lasarte JJ, Vera R, Kochan G, Escors D. CAR-T Cells for the Treatment of Lung Cancer. Life 2022;12:561. [DOI: 10.3390/life12040561] [Reference Citation Analysis]
15 Ingenwerth M, Brandenburg T, Führer-Sakel D, Goetz M, Weber F, Dralle H, Schildhaus HU, Schmid KW, Theurer S. DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas. Endocr Connect 2021;10:283-9. [PMID: 33617464 DOI: 10.1530/EC-20-0611] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Isobe Y, Sato K, Nishinaga Y, Takahashi K, Taki S, Yasui H, Shimizu M, Endo R, Koike C, Kuramoto N, Yukawa H, Nakamura S, Fukui T, Kawaguchi K, Chen-Yoshikawa TF, Baba Y, Hasegawa Y. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer. EBioMedicine 2020;52:102632. [PMID: 31981983 DOI: 10.1016/j.ebiom.2020.102632] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
17 Matsuo K, Taniguchi K, Hamamoto H, Inomata Y, Komura K, Tanaka T, Lee SW, Uchiyama K. Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview. Cancer Sci 2021;112:2984-92. [PMID: 34107132 DOI: 10.1111/cas.15017] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol 2019;12:61. [PMID: 31215500 DOI: 10.1186/s13045-019-0745-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
19 Alì G, Di Stefano I, Poma AM, Ricci S, Proietti A, Davini F, Lucchi M, Melfi F, Fontanini G. Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms. Front Oncol 2021;11:729765. [PMID: 34568063 DOI: 10.3389/fonc.2021.729765] [Reference Citation Analysis]
20 Furuta M, Kikuchi H, Shoji T, Takashima Y, Kikuchi E, Kikuchi J, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail. Cancer Sci 2019;110:1599-608. [PMID: 30874360 DOI: 10.1111/cas.13997] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
21 Matsuo K, Taniguchi K, Hamamoto H, Ito Y, Futaki S, Inomata Y, Shima T, Asakuma M, Lee SW, Tanaka K, Okuda J, Kondo Y, Uchiyama K. Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy. Cancer Sci 2019;110:3122-31. [PMID: 31369178 DOI: 10.1111/cas.14157] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
22 Ko J, Winslow MM, Sage J. Mechanisms of small cell lung cancer metastasis. EMBO Mol Med 2021;13:e13122. [PMID: 33296145 DOI: 10.15252/emmm.202013122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
23 Morgensztern D, Johnson M, Rudin CM, Rossi M, Lazarov M, Brickman D, Fong A. SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. Lung Cancer 2020;145:126-31. [PMID: 32438272 DOI: 10.1016/j.lungcan.2020.04.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]